Last reviewed · How we verify
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma (ICAR)
The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.
Details
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | PHASE1 |
| Status | RECRUITING |
| Enrolment | 27 |
| Start date | Fri Aug 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Apr 27 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Small Cell Lung Cancer
Interventions
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy
- acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Countries
France, Monaco